hPCL3S promotes proliferation and migration of androgen-independent prostate cancer cells.

PHF19 PRC2 hPCL3S prostate cancer β-catenin

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
24 Mar 2020
Historique:
received: 19 09 2019
accepted: 17 02 2020
entrez: 8 4 2020
pubmed: 8 4 2020
medline: 8 4 2020
Statut: epublish

Résumé

Polycomb repressive complex 2 (PRC2) allows the deposition of H3K27me3. PRC2 facultative subunits modulate its activity and recruitment such as hPCL3/PHF19, a human ortholog of Drosophila Polycomb-like protein (PCL). These proteins contain a TUDOR domain binding H3K36me3, two PHD domains and a "Winged-helix" domain involved in GC-rich DNA binding. The human PCL3 locus encodes the full-length hPCL3L protein and a shorter isoform, hPCL3S containing the TUDOR and PHD1 domains only. In this study, we demonstrated by RT-qPCR analyses of 25 prostate tumors that hPCL3S is frequently up-regulated. In addition, hPCL3S is overexpressed in the androgen-independent DU145 and PC3 cells, but not in the androgen-dependent LNCaP cells.

Identifiants

pubmed: 32256978
doi: 10.18632/oncotarget.27511
pii: 27511
pmc: PMC7105160
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1051-1074

Déclaration de conflit d'intérêts

CONFLICTS OF INTEREST The authors declare no disclosure of potential conflicts of interest.

Références

Nature. 2018 Sep;561(7721):127-131
pubmed: 30150773
Mol Cancer. 2010 Mar 10;9:55
pubmed: 20219091
Tumour Biol. 2016 Sep;37(9):12241-12250
pubmed: 27240591
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Trends Biochem Sci. 2011 Jul;36(7):364-72
pubmed: 21514168
Genome Biol. 2014;15(12):550
pubmed: 25516281
Cell. 2017 Sep 21;171(1):163-178.e19
pubmed: 28844694
Nature. 2011 Jan 20;469(7330):343-9
pubmed: 21248841
J Mol Med (Berl). 2005 Dec;83(12):1014-24
pubmed: 16211407
Bioessays. 2016 May;38(5):446-54
pubmed: 27000413
Prostate. 2000 Feb 15;42(3):186-95
pubmed: 10639189
Nat Commun. 2019 Jan 17;10(1):278
pubmed: 30655535
Clin Cancer Res. 2017 May 1;23(9):2245-2254
pubmed: 27799248
Nature. 2017 Sep 14;549(7671):287-291
pubmed: 28869966
Oncotarget. 2016 Mar 22;7(12):14220-40
pubmed: 26871947
Nat Rev Genet. 2019 Oct;20(10):599-614
pubmed: 31267064
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22189-22195
pubmed: 31611391
Cell Cycle. 2016;15(3):305-6
pubmed: 26652297
Nat Rev Mol Cell Biol. 2017 Jan;18(1):18-30
pubmed: 27677860
Blood. 2019 Oct 3;134(14):1176-1189
pubmed: 31383640
Prostate. 2011 Nov;71(15):1668-79
pubmed: 21432867
Oncogene. 2014 Apr 24;33(17):2204-14
pubmed: 23708657
J Biol Chem. 2012 Mar 23;287(13):10509-24
pubmed: 22315224
Am J Transl Res. 2015 Feb 15;7(2):175-93
pubmed: 25901190
Front Oncol. 2014 Mar 25;4:60
pubmed: 24724054
Genes Dev. 2018 Sep 1;32(17-18):1105-1140
pubmed: 30181359
Nat Rev Cancer. 2016 Dec;16(12):803-810
pubmed: 27658528
Nat Struct Mol Biol. 2012 Dec;19(12):1273-81
pubmed: 23160351
Mol Cell. 2018 Mar 1;69(5):840-852.e5
pubmed: 29499137
Genes Dev. 2015 Nov 1;29(21):2231-43
pubmed: 26494712
Cell. 2017 Sep 21;171(1):34-57
pubmed: 28938122
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Cancer Res. 2003 Nov 1;63(21):7056-61
pubmed: 14612495
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Biol Chem. 2013 Apr 12;288(15):10254-64
pubmed: 23417673
Nat Struct Mol Biol. 2012 Dec;19(12):1257-65
pubmed: 23104054
J Biol Chem. 2001 Nov 16;276(46):43065-73
pubmed: 11571280
FEBS J. 2015 May;282(9):1723-35
pubmed: 25271128
Cell Stem Cell. 2012 May 4;10(5):556-69
pubmed: 22560078
Cell Death Dis. 2018 Oct 15;9(11):1049
pubmed: 30323224
Cancer Res. 2018 May 15;78(10):2536-2549
pubmed: 29483096
Nat Genet. 2018 Jul;50(7):1002-1010
pubmed: 29808031
Mol Cell. 2013 Feb 7;49(3):571-82
pubmed: 23273982
J Biol Chem. 2006 Dec 15;281(50):38905-17
pubmed: 17030513
Trends Biochem Sci. 2006 Jan;31(1):35-40
pubmed: 16297627
Hum Mol Genet. 2003 Feb 15;12(4):441-50
pubmed: 12566391
Oncotarget. 2016 Mar 8;7(10):11018-32
pubmed: 26783961
Mol Cancer Res. 2011 Jul;9(7):914-24
pubmed: 21669963
Trends Biochem Sci. 2017 Jul;42(7):531-542
pubmed: 28483375
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Biochem J. 2011 Mar 1;434(2):333-42
pubmed: 21143197
Trends Biochem Sci. 1995 Feb;20(2):56-9
pubmed: 7701562
Mol Cell. 2011 Sep 16;43(6):853-66
pubmed: 21925375
Gene. 2004 Dec 8;343(1):69-78
pubmed: 15563832
Trends Cell Biol. 2019 Aug;29(8):660-671
pubmed: 31178244
PLoS Genet. 2012;8(3):e1002576
pubmed: 22438827

Auteurs

Souhila Abdelfettah (S)

University de Lille, CNRS, Institut Pasteur de Lille, UMR 8161m M3T, Mechanisms of Tumorigenesis and Targeted Therapies, F-59000 Lille, France.

Gaylor Boulay (G)

Department of Pathology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

Marion Dubuissez (M)

Present Address: Maisonneuve-Rosemont Hospital Research Center, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 3W5, Canada.

Nathalie Spruyt (N)

University de Lille, CNRS, Institut Pasteur de Lille, UMR 8161m M3T, Mechanisms of Tumorigenesis and Targeted Therapies, F-59000 Lille, France.

Sara P Garcia (SP)

Department of Pathology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

Shruthi Rengarajan (S)

Department of Pathology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

Ingrid Loison (I)

University de Lille, CNRS, Institut Pasteur de Lille, UMR 8161m M3T, Mechanisms of Tumorigenesis and Targeted Therapies, F-59000 Lille, France.

Xavier Leroy (X)

Department of Pathology, University de Lille, CHU de Lille, F-59000 Lille, France.

Miguel N Rivera (MN)

Department of Pathology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

Dominique Leprince (D)

University de Lille, CNRS, Institut Pasteur de Lille, UMR 8161m M3T, Mechanisms of Tumorigenesis and Targeted Therapies, F-59000 Lille, France.

Classifications MeSH